Immune-Onc Therapeutics Announces Key Executive Appointments and Series B Funding
In addition, Immune-Onc announced it received Series B funding of more than $33 million from leading investors, including Northern Light Venture Capital, Vivo Capital, and the Stanford-StartX Fund, to advance its pipeline programs.
“As we prepare to move from translational research into the clinic, Adrian and An’s decades of industry expertise in drug development will be critical in advancing our mission to develop novel biotherapeutics for hard-to-treat cancers,” said Charlene Liao, Ph.D., co-founder, president and chief executive officer of Immune-Onc Therapeutics. “Adrian and An embody many of the core values of Immune-Onc: dedication to patients, passion for science, and excellence in execution. I am delighted to have them join Immune-Onc’s leadership team.”
As Chief Medical Officer, Dr. Jubb is accountable for the clinical and regulatory strategy and execution of Immune-Onc’s portfolio. As Senior Vice President of Development Sciences, Dr. Song has overall accountability for translational development of Immune-Onc’s portfolio, including preclinical PKPD and toxicology evaluation, clinical pharmacology, bioanalytical and biomarker/diagnostic development and certain analytical aspects of technical development. Both Dr. Jubb and Dr. Song are based at Immune-Onc’s headquarters in Palo Alto and will join the company’s Executive Committee.
About Dr. Adrian Jubb
Adrian Jubb, M.B. Ch.B., Ph.D., F.R.C.Path., is a physician-scientist with 17 years of experience across research and clinical development in oncology, infectious disease and neuroscience. Most recently, Dr. Jubb served as Vice President and Head of Early Development at Achaogen, where he played a leading role in the development and FDA approval of ZEMDRITM for the treatment of serious multi-drug resistant infections. Prior to Achaogen, Dr. Jubb was a Medical Director in Oncology at Genentech and supported numerous oncology clinical development programs over the course of his tenure, including AVASTIN®, MetMAb, COTELLIC® and Apo2L.
Dr. Jubb holds an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree, with honors, from the Faculty of Medicine and Health at the University of Leeds, United Kingdom. His scientific training was conducted in the research laboratories of Genentech, leading to the award of a Ph.D. through the University of Leeds. Dr. Jubb is also a Fellow of the Royal College of Pathologists (F.R.C.Path.), having completed joint clinical and academic postgraduate training at the Oxford Deanery and the University of Oxford, United Kingdom. Following his training, Dr. Jubb was appointed to a faculty position in the Nuffield Department of Clinical Laboratory Sciences, University of Oxford, where he led several projects in the fields of angiogenesis and oncology as a principal investigator. Dr. Jubb has authored over 55 scientific publications, including numerous first and senior author papers in top-tier journals (e.g., Journal of Clinical Oncology, Lancet Oncology, Nature Reviews Cancer), and is a named inventor on 4 issued patents.
About Dr. An Song
An Song, Ph.D., is a translational scientist with 22 years of experience across basic research and drug development in oncology, autoimmunity, metabolic, infectious, and neurodegenerative diseases. Dr. Song joins Immune-Onc from Genentech where, as a Senior Director in BioAnalytical Sciences, she led the Assay Development and Technology group for the company’s large molecule portfolio globally and was a member of numerous scientific review bodies within the Genentech Research and Early Development (gRED) organization. During her 16-year tenure at Genentech, Dr. Song contributed to, and oversaw 40+ IND/CTA and BLA/MAA regulatory filings for products including Rituxan@, Avastin®, Herceptin®, Lucentis®, Kadcyla® and Tecentriq®. In addition, Dr. Song played a significant role in the development and approval of Ocrevus®.
Dr. Song holds a B.S. in Biochemistry from Nanjing University in China. She received her Ph.D. in Biochemistry & Molecular Biology from Indiana University and completed a postdoctoral fellowship in immunology at Stanford University. Upon completion of postdoctoral work in T-cell activation she joined Stanford as a Research Assistant Professor and as faculty of the Immunology Program. Dr. Song has published a number of original manuscripts, review articles and book chapters, as well as contributed to several industry white papers on immunogenicity and antibody Fc effector function evaluation. She is an active member of American Association of Pharmaceutical Scientist (AAPS), having served as an executive member of the Biotech Section and the chair of Therapeutic Product Immunogenicity (TPI) Focus Group/Community.
About Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients. The company aims to translate unique scientific insights in the tumor microenvironment and immune suppressive pathways to develop first-in-class biotherapeutics. Immune-Onc has a promising pipeline built upon strategic collaborations and cutting-edge research from The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. For more information, please visit www.immune-onc.com.
Cooper Communication Group
Tara Cooper, 650-303-7306
Source: Immune-Onc Therapeutics, Inc.